Filtered By:
Education: Academia
Procedure: Angioplasty
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 243 results found since Jan 2013.
Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention
Platelets. 2021 Apr 4:1-8. doi: 10.1080/09537104.2021.1909717. Online ahead of print.ABSTRACTIt remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in Chinese patients with ACS undergoing percutaneous coronary intervention (PCI). In this observational cohort study, a total of 2110 ACS patients who were event-free at 3 months after the index PCI were divided into standard-dose ticagrelor (90 mg twice daily) (n = 1830) or low-dose ticagre...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Yue Wang Beibei Liu Leilei Chen Yue Wang Zhiqiang Wang Xiaojiang Zhang Min Suo Gary S Mintz Xiaofan Wu Source Type: research
Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients
In conclusion, poor metabolizers of CYP2C19 and TT groups of P2Y12 G52T may be significant predictors of poor clinical outcomes in elderly patients.PMID:33707344 | DOI:10.18632/aging.202799
Source: Aging - March 12, 2021 Category: Biomedical Science Authors: Jung-Joon Cha Jae Hyoung Park Hyung Joon Joo Soon Jun Hong Tae Hoon Ahn Byeong-Keuk Kim WonYong Shin Sung Gyun Ahn JungHan Yoon Yong Hoon Kim Yun-Hyeong Cho Woong Chol Kang Weon Kim Young-Hyo Lim Hyeon Cheol Gwon Woong Gil Choi Do-Sun Lim Source Type: research
Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention - From the CREDO-Kyoto Registry Cohort-3.
CONCLUSIONS: The J-HBR criteria successfully identified those patients with very high bleeding risk after PCI, who represented 64% of patients in this all-comers registry.
PMID: 33298644 [PubMed - as supplied by publisher]
Source: Circulation Journal - December 8, 2020 Category: Cardiology Authors: Natsuaki M, Morimoto T, Shiomi H, Ehara N, Taniguchi R, Tamura T, Tada T, Suwa S, Kaneda K, Watanabe H, Tazaki J, Watanabe S, Yamamoto E, Saito N, Fuki M, Takeda T, Eizawa H, Shinoda E, Mabuchi H, Shirotani M, Uegaito T, Matsuda M, Takahashi M, Inoko M, T Tags: Circ J Source Type: research
Ticagrelor or Prasugrel in Patients with ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Conclusions: In patients with STEMI undergoing primary PCI, there was no significant difference in the primary endpoint between prasugrel and ticagrelor. Ticagrelor was associated with a significant increase in the risk for recurrent myocardial infarction. Clinical Trial Registration: URL: https://www.clinicaltrials.gov; Unique identifier NCT01944800.
PMID: 33115278 [PubMed - as supplied by publisher]
Source: Circulation - October 29, 2020 Category: Cardiology Authors: Aytekin A, Ndrepepa G, Neumann FJ, Menichelli M, Mayer K, Wöhrle J, Bernlochner I, Lahu S, Richardt G, Witzenbichler B, Sibbing D, Cassese S, Angiolillo DJ, Valina C, Kufner S, Liebetrau C, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Wustrow I, Joner M, T Tags: Circulation Source Type: research
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
Conclusion Among patients with or without NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS.Trial registrationClinicaltrials.gov identifier: NCT02270242.
Source: European Heart Journal - October 20, 2020 Category: Cardiology Source Type: research
Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionDiscontinuing ASA after short-term use for the treatment of patients with T2DM following PCI was not associated with any increased cardiovascular outcomes. Also, discontinuing ASA after short-term use and continuing the use of a P2Y12 inhibitor were somewhat safer in these patients with T2DM. Further research should follow.
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research
Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials
ConclusionIn patients with ACS undergoing PCI, both prasugrel and ticagrelor were associated with similar cardiovascular outcomes and adverse bleeding events.
Source: Cardiovascular Drugs and Therapy - August 19, 2020 Category: Cardiology Source Type: research
Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis.
CONCLUSIONS: This systematic review provides moderate-quality evidence showing that ET, compared with CMT, in people with recent symptomatic severe intracranial atherosclerotic stenosis probably does not prevent recurrent stroke and appears to carry an increased hazard. The impact of delayed ET intervention (more than three weeks after a qualifying event) is unclear and may warrant further study.
PMID: 32789891 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - August 10, 2020 Category: General Medicine Authors: Wang T, Luo J, Wang X, Yang K, Jadhav V, Gao P, Ma Y, Zhao N, Jiao L Tags: Cochrane Database Syst Rev Source Type: research
A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs. Ticagrelor in Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention: rationale and design of the TALOS-AMI trial.
CONCLUSIONS: The TALOS-AMI trial is the first large-scale, multicenter, randomized study exploring the efficacy and safety of the de-escalating antiplatelet therapy that switches ticagrelor to clopidogrel in stabilized AMI patients undergoing PCI.
PMID: 32718912 [PubMed - as supplied by publisher]
Source: EuroIntervention - July 30, 2020 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
ConclusionsThis meta-analysis showed a significantly lowered risk of major bleeding and similar benefits of P2Y12 inhibitor monotherapy after short-term DAPT compared with standard-term DAPT in patients undergoing PCI.
Source: Clinical Drug Investigation - July 12, 2020 Category: Drugs & Pharmacology Source Type: research
